Skip to main content
Fig. 2 | BMC Cancer

Fig. 2

From: Efficacy and acquired resistance of EGFR-TKI combined with chemotherapy as first-line treatment for Chinese patients with advanced non-small cell lung cancer in a real-world setting

Fig. 2

Progression-free survival in different subgroups a EGFR exon 19 deletion subgroup; b EGFR exon 21L858R subgroup; c EGFR high abundance subgroup; d EGFR low abundance subgroup. T + C, EGFR-TKI combined with chemotherapy; T, EGFR-TKI monotherapy; PFS, progression-free survival; OS, overall survival

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us